Market Summary
USD9.62-0.10
Delayedas of 27 Sep 2023, 11:20 am-1.03%
VTRS Stock Price
VTRS RSI Chart
VTRS Valuation
VTRS Price/Sales (Trailing)
VTRS Profitability
VTRS Fundamentals
VTRS Revenue
VTRS Earnings
Price Action
52 Week Range
8.3512.40
(Low)(High)
Last 7 days
-1.7%
Last 30 days
-11.4%
Trailing 12 Months
15.2%
VTRS Financial Health
VTRS Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for VTRS
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-03-06 | Ni Xiangyang (Sean) | sold | -34,890 | 11.0835 | -3,148 | president, greater china |
2023-03-04 | Narula Sanjeev | acquired | - | - | 40,287 | chief financial officer |
2023-03-04 | CORNWELL W DON | acquired | - | - | 20,313 | - |
2023-03-04 | GOETTLER MICHAEL | acquired | - | - | 107,827 | chief executive officer |
2023-03-04 | Mauro Anthony | acquired | - | - | 37,917 | see remarks |
2023-03-04 | van der Meer Mohr Pauline | acquired | - | - | 20,313 | - |
2023-03-04 | Cuneo Andrew | sold (taxes) | -32,188 | 11.13 | -2,892 | see remarks |
2023-03-04 | Campbell Paul | acquired | - | - | 18,515 | see remarks |
2023-03-04 | Cuneo Andrew | acquired | - | - | 6,518 | see remarks |
2023-03-04 | Narula Sanjeev | sold (taxes) | -194,964 | 11.13 | -17,517 | chief financial officer |
Which funds bought or sold VTRS recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-21 | Baystate Wealth Management LLC | added | 3.44 | 863 | 12,614 | -% |
2023-09-20 | BARCLAYS PLC | added | 70.49 | 10,704,000 | 24,626,000 | 0.02% |
2023-09-19 | BIRMINGHAM CAPITAL MANAGEMENT CO INC/AL | reduced | -13.52 | -77,830 | 678,735 | 0.28% |
2023-09-13 | CGC Financial Services, LLC | new | - | 2,046 | 2,046 | -% |
2023-09-12 | Farther Finance Advisors, LLC | added | 21.59 | 9,424 | 45,469 | 0.01% |
2023-09-08 | TUCKER ASSET MANAGEMENT LLC | added | 62.39 | 776 | 1,898 | -% |
2023-09-07 | ST GERMAIN D J CO INC | new | - | 56,437 | 56,437 | -% |
2023-09-05 | Delos Wealth Advisors, LLC | added | 0.76 | 60.00 | 1,321 | -% |
2023-08-28 | DT Investment Partners, LLC | unchanged | - | 928 | 11,028 | -% |
2023-08-24 | Alberta Investment Management Corp | reduced | -97.75 | -6,863,970 | 164,151 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of Viatris
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 09, 2023 | vanguard group inc | 12.31% | 149,318,666 | SC 13G/A | |
| Feb 07, 2023 | state street corp | 5.10% | 61,903,672 | SC 13G | |
| Jan 31, 2023 | blackrock inc. | 7.7% | 93,214,306 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 4.57% | 55,233,099 | SC 13G/A | |
| Feb 03, 2022 | blackrock inc. | 7.2% | 86,554,658 | SC 13G/A | |
| Feb 04, 2021 | wellington management group llp | 5.74% | 69,811,210 | SC 13G | |
| Feb 02, 2021 | blackrock inc. | 7.3% | 89,526,414 | SC 13G | |
| Jan 08, 2021 | vanguard group inc | 10.62% | 129,072,141 | SC 13G |
Recent SEC filings of Viatris
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Aug 07, 2023 | 8-K | Current Report | |
| Aug 07, 2023 | 10-Q | Quarterly Report |
Peers (Alternatives to Viatris)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
AAPL | 2.7T | 383.9B | -3.72% | 14.24% | 28.4 | 7.01 | -0.93% | -4.89% |
MSFT | 2.3T | 211.9B | -3.36% | 31.83% | 32.06 | 10.95 | 6.88% | -0.52% |
GOOG | 1.6T | 289.5B | -0.95% | 31.01% | 26.82 | 5.65 | 4.10% | -15.36% |
AMZN | 1.3T | 538.0B | -5.46% | 9.41% | 99.39 | 2.41 | 10.73% | 12.62% |
| MID-CAP | ||||||||
JBLU | 1.5B | 9.9B | -27.56% | -33.79% | 54.14 | 0.15 | 24.14% | 106.11% |
NYMT | 766.5M | 246.5M | -8.20% | 4.63% | -4.82 | 3.11 | 6.65% | -174.04% |
| SMALL-CAP | ||||||||
TLRY | 1.6B | 627.1M | -7.75% | -11.11% | -1.08 | 2.51 | -0.20% | -204.67% |
PLAY | 1.5B | 2.2B | -9.70% | 14.84% | 10.83 | 0.7 | 38.20% | -10.10% |
NKLA | 1.2B | 56.2M | 14.50% | -61.04% | -1.37 | 20.54 | 40.31% | -12.26% |
MFA | 1.0B | 543.3M | -6.71% | 14.01% | -692.78 | 1.85 | 31.74% | 78.13% |
BYND | 602.7M | 356.8M | -18.87% | -35.56% | -2.14 | 1.69 | -23.03% | 15.53% |
CGC | 507.6M | 453.3M | 136.46% | -66.34% | -0.41 | 1.12 | -16.04% | 55.90% |
GPRO | 486.9M | 1.0B | -15.55% | -36.87% | -18.42 | 0.47 | -11.34% | -107.10% |
INO | 99.4M | 13.7M | -11.02% | -77.34% | -0.59 | 7.28 | 413.65% | 52.51% |
Viatris News
Returns for VTRS
Cumulative Returns on VTRS
-12.3%
10-Year Cumulative Returns
-17.9%
7-Year Cumulative Returns
-22.5%
5-Year Cumulative Returns
-10.4%
3-Year Cumulative Returns
Risks for VTRS
What is the probability of a big loss on VTRS?
100%
Probability that Viatris stock will be more than 20% underwater in next one year
71.5%
Probability that Viatris stock will be more than 30% underwater in next one year.
30%
Probability that Viatris stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does VTRS drawdown profile look like?
Y-axis is the maximum loss one would have experienced if Viatris was unfortunately bought at previous high price.
Drawdowns
Financials for Viatris
Income Statement (Last 12 Months)(In Millions)
| Income Statement (Last 12 Months) | (In Millions) | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2018Q4 |
| Revenue | -1.3% | 15,602 | 15,800 | 16,263 | 16,728 | 17,187 | 17,648 | 17,886 | 17,168 | 15,604 | 13,757 | 11,946 | 11,097 | 10,701 | 10,477 | 11,501 | 11,434 |
| Gross Profit | -1.5% | 6,173 | 6,268 | 6,497 | 6,769 | 6,595 | 6,219 | 5,576 | 4,736 | 4,320 | 4,018 | 3,797 | 4,120 | 3,864 | 3,624 | 3,898 | 4,002 |
| Operating Expenses | 1.7% | 5,046 | 4,961 | 4,882 | 5,031 | 5,059 | 5,280 | 5,610 | 5,573 | 5,164 | 4,680 | 4,008 | 3,227 | 2,151 | 962 | 3,182 | 3,096 |
| S&GA Expenses | 1.2% | 4,274 | 4,223 | 4,179 | 3,997 | 4,034 | 4,258 | 4,529 | 4,808 | 4,411 | 3,926 | 3,345 | 2,644 | 2,650 | 2,422 | 2,564 | 2,441 |
| R&D Expenses | 8.8% | 755 | 694 | - | 747 | 724 | 709 | 751 | 639 | 616 | 625 | 555 | 534 | 541 | 457 | 640 | 705 |
| EBITDA | -100.0% | - | 6,223 | 6,433 | 4,642 | 4,730 | 4,738 | 4,478 | 4,660 | 3,573 | 3,323 | 1,993 | 2,442 | 2,160 | 2,140 | 2,691 | 2,951 |
| EBITDA Margin | -100.0% | - | 0.39* | 0.40* | 0.28* | 0.28* | 0.27* | 0.25* | 0.27* | 0.23* | 0.24* | 0.17* | 0.22* | 0.20* | 0.20* | 0.23* | 0.26* |
| Interest Expenses | -0.4% | 591 | 593 | 592 | 594 | 592 | 613 | 636 | 632 | 598 | 547 | 498 | 471 | 472 | 480 | 517 | 542 |
| Earnings Before Taxes | -2.2% | 2,552 | 2,608 | 2,813 | 1,140 | 913 | 304 | -664 | -1,474 | -1,432 | -1,193 | -721 | 390 | 68.00 | 41.00 | 154 | 298 |
| EBT Margin | -100.0% | - | 0.17* | 0.17* | 0.07* | 0.05* | 0.02* | -0.04* | -0.06* | -0.09* | -0.05* | -0.06* | 0.03* | 0.00* | - | 0.01* | 0.03* |
| Net Income | -2.6% | 1,854 | 1,904 | 2,079 | 804 | 761 | 168 | -1,269 | -1,921 | -2,046 | -1,728 | -669 | 328 | 80.00 | 28.00 | 17.00 | 353 |
| Net Income Margin | -100.0% | - | 0.12* | 0.13* | 0.05* | 0.04* | 0.01* | -0.07* | -0.09* | -0.13* | -0.12* | -0.06* | -0.02* | 0.00* | - | - | 0.03* |
| Free Cashflow | -100.0% | - | 2,396 | 2,547 | 2,883 | 3,083 | 2,834 | 2,560 | 3,348 | 1,676 | 1,540 | 989 | -166 | 718 | 215 | -213 | 2,090 |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2019Q4 |
| Assets | -1.2% | 48,695 | 49,290 | 50,022 | 48,663 | 51,125 | 53,467 | 54,843 | 56,070 | 57,984 | 58,979 | 61,553 | 11,413 | 11,412 | 31,256 |
| Current Assets | 1.5% | 9,778 | 9,630 | 10,635 | 10,488 | 11,177 | 11,744 | 10,903 | 11,308 | 11,750 | 12,319 | 12,868 | 11,413 | 11,412 | 6,757 |
| Cash Equivalents | 24.2% | 629 | 507 | 1,260 | 647 | 665 | 752 | 706 | 757 | 674 | 807 | 844 | 665 | 324 | 491 |
| Inventory | -0.6% | 3,642 | 3,664 | 3,520 | 3,380 | 3,613 | 3,797 | 3,978 | 4,082 | 4,488 | 4,942 | 5,472 | - | - | 2,671 |
| Net PPE | -0.8% | 2,983 | 3,008 | 3,025 | 3,039 | 3,084 | 3,150 | 3,189 | 3,114 | 3,171 | 3,247 | 3,460 | - | - | 2,150 |
| Goodwill | -0.4% | 10,533 | 10,573 | 10,426 | 10,055 | 10,523 | 10,979 | 12,114 | 12,170 | 11,990 | 11,907 | 12,347 | - | - | 9,591 |
| Liabilities | -1.8% | 27,852 | 28,362 | 28,950 | 29,480 | 31,320 | 33,019 | 34,350 | 34,929 | 36,777 | 37,565 | 38,599 | 11,614 | 11,413 | 19,372 |
| Current Liabilities | 6.8% | 6,524 | 6,108 | 6,746 | 6,521 | 7,681 | 9,643 | 9,884 | 10,104 | 10,133 | 9,978 | 10,563 | 79.00 | 28.00 | 5,569 |
| Short Term Borrowings | -88.7% | 23.00 | 205 | - | 500 | 1,020 | 655 | 1,493 | 1,707 | 1,301 | 37.00 | 1,100 | - | - | - |
| LT Debt, Current | 162.3% | 1,334 | 509 | 1,259 | 764 | 768 | 2,606 | 1,878 | 1,908 | 2,184 | 2,300 | 2,309 | - | - | 1,508 |
| LT Debt, Non Current | -4.6% | 17,246 | 18,069 | 18,015 | 18,725 | 19,206 | 18,763 | 19,717 | 19,854 | 20,917 | 22,102 | 22,429 | 11,535 | 11,385 | 11,214 |
| Shareholder's Equity | -0.4% | 20,843 | 20,928 | 21,072 | 19,182 | 19,805 | 20,448 | 20,493 | 21,141 | 21,207 | 21,415 | 22,954 | 12,548 | 11,746 | 11,884 |
| Retained Earnings | 2.2% | 5,369 | 5,253 | 5,176 | 4,313 | 4,107 | 3,942 | 3,689 | 4,087 | 3,910 | 4,324 | 5,361 | -170 | -0.90 | 6,031 |
| Additional Paid-In Capital | 0.2% | 18,719 | 18,680 | 18,646 | 18,617 | 18,586 | 18,555 | 18,536 | 18,514 | 18,490 | 18,465 | 18,439 | -31.00 | -0.30 | 8,644 |
| Shares Outstanding | -100.0% | - | 1,203 | - | 1,213 | 1,212 | 1,211 | - | 1,209 | 1,209 | 1,208 | - | 517 | 517 | - |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | ||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2018Q4 |
| Cashflow From Operations | -10.3% | 2,498 | 2,785 | 2,953 | 3,333 | 3,550 | 3,307 | 3,017 | 2,530 | 1,969 | 1,790 | 1,232 | 1,594 | 894 | 388 | 1,804 | - | - | 2,342 |
| Share Based Compensation | 7.5% | 141 | 131 | 116 | 109 | 105 | 107 | 111 | 118 | 108 | 93.00 | 79.00 | 66.00 | 69.00 | 78.00 | 57.00 | - | - | -3.30 |
| Cashflow From Investing | 0.7% | 843 | 838 | 1,521 | -483 | -486 | -421 | -117 | 79.00 | 139 | 81.00 | -301 | -371 | -293 | -194 | -525 | - | - | -1,210 |
| Cashflow From Financing | 12.4% | -3,367 | -3,843 | -3,877 | -2,896 | -3,015 | -2,921 | -3,012 | -2,513 | -1,781 | -1,680 | -605 | -1,006 | -812 | -33.07 | -1,169 | - | - | -1,090 |
| Dividend Payments | - | - | - | - | - | - | - | - | 532 | - | - | - | - | - | - | - | - | - | - |
| Buy Backs | 0% | 500 | 500 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 432 |
VTRS Income Statement
2023-06-30Condensed Consolidated Statements Of Operations - USD ($) shares in Millions, $ in Millions | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Net sales | $ 3,909.5 | $ 4,105.4 | $ 7,628.6 | $ 8,283.6 |
| Total revenues | 3,918.6 | 4,116.8 | 7,647.7 | 8,308.5 |
| Cost of sales | 2,310.0 | 2,413.5 | 4,496.9 | 4,834.0 |
| Gross profit | 1,608.6 | 1,703.3 | 3,150.8 | 3,474.5 |
| Operating expenses: | ||||
| Research and development | 208.3 | 162.6 | 391.2 | 304.9 |
| Payments to Acquire in Process Research and Development | 10.2 | 0.0 | 10.2 | 0.0 |
| Selling, general and administrative | 1,031.9 | 981.1 | 1,990.8 | 1,896.4 |
| Litigation settlements and other contingencies, net | (11.0) | 10.9 | (10.4) | 17.1 |
| Total operating expenses | 1,239.4 | 1,154.6 | 2,381.8 | 2,218.4 |
| Earnings from operations | 369.2 | 548.7 | 769.0 | 1,256.1 |
| Interest expense | 143.7 | 145.9 | 290.7 | 292.1 |
| Other (income) expense, net | (107.5) | 13.5 | (177.4) | 47.2 |
| Earnings before income taxes | 333.0 | 389.3 | 655.7 | 916.8 |
| Income tax (benefit) provision | 69.0 | 75.4 | 167.0 | 203.7 |
| Net earnings (loss) | $ 264.0 | $ 313.9 | $ 488.7 | $ 713.1 |
| Earnings per share attributable to Viatris Inc. shareholders | ||||
| Basic (in USD per share) | $ 0.22 | $ 0.26 | $ 0.41 | $ 0.59 |
| Diluted (in USD per share) | $ 0.22 | $ 0.26 | $ 0.41 | $ 0.59 |
| Weighted average shares outstanding: | ||||
| Basic | 1,212.3 | 1,211.4 | ||
| Diluted | 1,217.1 | 1,215.1 | ||
| Other Revenues | ||||
| Other revenues | $ 9.1 | $ 11.4 | $ 19.1 | $ 24.9 |
VTRS Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Millions | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets: | ||
| Cash and cash equivalents | $ 629.2 | $ 1,259.9 |
| Accounts receivable, net | 3,607.3 | 3,814.5 |
| Inventories | 3,641.5 | 3,519.5 |
| Prepaid expenses and other current assets | 1,725.1 | 1,811.2 |
| Assets held for sale | 174.9 | 230.3 |
| Total current assets | 9,778.0 | 10,635.4 |
| Property, plant and equipment, net | 2,983.2 | 3,024.5 |
| Intangible assets, net | 22,084.4 | 22,607.1 |
| Goodwill | 10,532.5 | 10,425.8 |
| Deferred income tax benefit | 966.0 | 925.9 |
| Other assets | 2,351.1 | 2,403.5 |
| Total assets | 48,695.2 | 50,022.2 |
| Current liabilities: | ||
| Accounts payable | 1,962.0 | 1,766.6 |
| Short-term borrowings | 23.2 | 0.0 |
| Income taxes payable | 158.1 | 279.6 |
| Current portion of long-term debt and other long-term obligations | 1,334.4 | 1,259.1 |
| Other current liabilities | 3,046.1 | 3,440.9 |
| Total current liabilities | 6,523.8 | 6,746.2 |
| Long-term debt | 17,246.0 | 18,015.2 |
| Deferred income tax liability | 2,407.8 | 2,432.0 |
| Other long-term obligations | 1,674.3 | 1,756.5 |
| Total liabilities | 27,851.9 | 28,949.9 |
| Viatris Inc. shareholders’ equity | ||
| Common Stock, Value, Issued | 12.2 | 12.1 |
| Additional paid-in capital | 18,719.4 | 18,645.8 |
| Retained earnings | 5,369.1 | 5,175.6 |
| Accumulated other comprehensive loss | (3,005.6) | (2,761.2) |
| Total Mylan N.V. equity, before treasury stock | 21,095.1 | 21,072.3 |
| Total equity | 20,843.3 | 21,072.3 |
| Total liabilities and equity | $ 48,695.2 | $ 50,022.2 |
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides its medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as offers biosimilars franchises, including Fulphila, Ogivri, Hulio, and SEMGLEE. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.